ZVRA Stock Zevra Therapeutics (ZVRA, $9.36) Stochastic Oscillator left the oversold zone on February 02, 2026
at Tickeron.com
This is a signal that ZVRA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 74 similar cases where ZVRA's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:
ZVRA in upward trend: price rose above 50-day moving average on January 29, 2026
ZVRA moved above its 50-day moving average on January 29, 2026 date and that indicates a change from a downward trend to an upward trend. In of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 74 cases where ZVRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on February 02, 2026. You may want to consider a long position or call options on ZVRA as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ZVRA just turned positive on January 30, 2026. Looking at past instances where ZVRA's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for ZVRA crossed bullishly above the 50-day moving average on January 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZVRA advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 146 cases where ZVRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 50-day moving average for ZVRA moved below the 200-day moving average on December 31, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZVRA broke above its upper Bollinger Band on February 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.877) is normal, around the industry mean (27.519). P/E Ratio (19.511) is within average values for comparable stocks, (51.491). ZVRA's Projected Growth (PEG Ratio) (10.667) is very high in comparison to the industry average of (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (6.079) is also within normal values, averaging (331.843).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology